Skip to content

Use of Biological Mesh (RemodellingTM) and Hernia Graft (Biodesign Surgisis) for open tension-free inguinal hernia repair: A prospective, multi-center, single-blind, randomized controlled trial

Use of Biological Mesh (RemodellingTM) and Hernia Graft (Biodesign Surgisis) for open tension-free inguinal hernia repair: A prospective, multi-center, single-blind, randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010723
Enrollment
Unknown
Registered
2017-02-24
Start date
2014-04-23
Completion date
Unknown
Last updated
2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inguinal hernia

Interventions

Biological Mesh (RemodellingTM):open tension-free inguinal hernia repair
Surgisis Inguinal hernia Matrix :open tension-free inguinal hernia repair

Sponsors

Huadong Hospital Affiliated to Fudan Univercity
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Unilateral inguinal hernia diagnosed as Type I-III in accordance with the China Hernia Society Groin Hernia classification (2003) APPENDIX A; (2) Aged 18-75 years; (3) Male; (4) Patients with ASA physical status I-IIIAPPENDIX B; (5) Informed consent: a detailed description of the clinical trial was provided by physicians and an informed consent APPENDIXC was signed by the patient or a proxy decision maker.

Exclusion criteria

Exclusion criteria: (1) Recurrent hernia, incarcerated hernia or bilateral hernia; (2) Any status that might affect the correct evaluation of pains(patient who were noncompliant, blind or drug addicted or have mental illness,e.g., depression); (3) Patients who were allergic to study materials; (4) Surgical contraindications:local infection; abnormality detected in systemic examination; patients with previous history of severe drug allergy or a history of asthma, heart disease, liver disease, kidney disease, diabetes, blood diseases or other severe conditions of acute or chronic diseases; evident abnormality detected in laboratory tests; evident abnormality in blood, clotting and bleeding time, liver function or kidney function.

Design outcomes

Primary

MeasureTime frame
Efficacy rate (1-recurrence rate);

Secondary

MeasureTime frame
Incidence of surgical site infection;Degree of pain in resting and coughing state;Other complications.;

Countries

China

Contacts

Public ContactJianxiong Tang

Huadong Hospital Affiliated to Fudan Univercity

johnxiong@china.com+86 13901791469

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026